Novo Nordisk and Eli Lilly are moving to end compounding of their medicines for good. They say they are no longer in shortage ...

Certain Blue Cross Blue Shield plans have announced they won't cover the drugs for weight loss at all. States such as North ...

Eli Lilly and rival Novo Nordisk have been testing their drugs for conditions beyond obesity and diabetes. The U.S. Food and Drug Administration is set to decide on the use of Lilly's weight-loss ...

blockbuster type 2 diabetes and weight loss drug tirzepatide was no longer in shortage. Despite closing the case, however, the FDA said it is "carefully assessing the challenged decision and ...

Eli Lilly dominates today's market for weight loss drugs, with two blockbusters. A smaller company, a biotech player, aims to join this billion-dollar market and recently reported fantastic ...

Eli Lilly stock struggles despite 27% gains over the past year; RFK Jr.'s HHS appointment sparks GLP-1 drug fears ... his critical stance on GLP-1 weight-loss treatments could lead to reduced ...

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau ... That's unlike Eli Lilly's obesity drug, Zepbound ...

Weight loss benefits from Amgen's monthly injection MariTide miss investor expectations MariTide's trial results comparable to Novo Nordisk and Eli Lilly ... drug The mid-stage study also showed ...

UK Health Minister Wes Streeting announced last month that US drug manufacturer Eli Lilly will begin a five-year trial in Greater Manchester to test if the company’s weight loss drug could curb ...

Eli Lilly's weight-loss drug. She worries an FDA decision to declare Zepbound is no longer in shortage could jeopardize access to less expensive versions made by compounding pharmacies.